Short interest actually UP in the latest 2 week reporting period.
Short interest 333K shares on 2/28 vs. 289K on 2/14 (that was the day of the Feuerstein St.Valentines day massacre).
Data is based on SETTLEMENT, not trade date, thus only includes trading through 2/11. In spite of the big dip on 2/14 the short position has increased.
The bigger the short position, the bigger the panic buying on any good news.
Charles, why does LPTN keep pushing back trial results for Nexus Ph2 trial of iSONEP in wet AMD? Trial was supposed to be complete with results release in 2013, at yesterday's Roth Conference, Pancoast again implicitly pushed back results release date, now saying around the end of 2014. Why does Pancoast not talk about reasons for Nexus trial lack of progress?
Regarding the iSONEP Ph1 trial, were full results of the trial published anywhere? I can't find them.
At the Roth Presentation on Slide 15, Pancoast shows cherry picked data from the 15 patient, variable dose size, one injection per patient trial. Why does he not show trial data for Patient 4, 10, 11, 12, and 13? That is fully one third of the patients for which we are not shown data! Why? Did lesions actually grow in size? Why does he not show the actual change in lesion size for patients 5, 6, 7, 8, and 9? Why does the slide not show which dose each patient received? Was there a dose/benefit correlation? Lack of full data seems deceptive.
LPTN's bioactive lipid targeting platform may (or may not) work. It's in it's infancy. There is a decade and $100M+ of trials behind squalamine which has significant safety/efficacy data supporting it.. There is only nine patients worth of safety and questionable efficacy data for iSONEP that we've seen. Patients only received ONE INJECTION each!
As a new class of drug, the FDA is going to require large and lengthy trials before iSONEP ever sees approval. Two to three years at least I'd guess. One unwanted side effect in a 600 patient Ph3 trial and they'll be back at square one.
OHRP and LPTN two very different situations.
Exactly, Reg-FD says no new material statements allowed unless it is webcast or there is an 8k in advance. Thus I'd suspect it was a duplicate of last months presentation.
LPTN presented an update on iSONEP at the ROTH conference yesterday, there are slides, some cover the old trial results . There is a link to the webcast archive on the LPTN website.
I actually came across OHRP while researching LPTN last summer. I've followed them loosely since. LPTN CEO is a hypester, the antithesis of Dr. T. He likes to embellish the potential market opportunity of iSONEP more than he likes to talk the science. LPTN keeps pushing back the enrollment completion date for the Nexus PhII trial of iSONEP in we AMD. As of yesterday's presentation, they're not expecting trial results until the near the end of 2014. That is nearly a YEAR BEHIND ORIGINAL SCHEDULE.
I think they may be having trouble getting trial participants, strangely one of the arms in the PhII trial treats subjects with iSONEP alone (with no rescue injections of anti-VEGF). Would YOU want to be in the trial if there was a risk that you were treating your wet AMD with a potentially ineffective drug? Anyway, there seemed to be a wide deviation of efficacy among the patients and as you've said in the past, during presentations the CEO cherry picks the data to make results look better than they actually were.
The webcast is worth a listen.
yp_Josh. Prayer is not a sound investment strategy. There are no churches at Wall St & Broad.
What percentage of your portfolio is in OHRP? Clearly too much, because you are letting emotion drive your posts. You say you are new to investing and have 5K shares of OHRP which is roughly $90K, that's a lot of cash in one stock for someone who is new to investing.
I suggest you lighten up, in more ways than one.
I'm showing that OHRP is NOT going to be webcast (no hotlink to webcast on the schedule).
As of yesterday, the hotlink was live. Maybe it will come back, but as of now it looks like there is no webcast.
Taraporewala racking up some frequent flyer miles. Presenting at Roth Conf in Dana Point CA this Wed at 12pm PDT.
It is webcast.
Hard to believe he'd be doing all these presentations if he didn't have a good feeling about upcoming results.....
Check your inbox. I emailed from different account this time. Your security software might not like hotttttttttt mailllllllllll
You bet. They know if it's working or not. You know my nature, I cover my backside always. Prudent managers need to do the same thing.
I guess what I'm saying is I wouldn't be upset or fault them one bit if they sold some share right now.
And there are probably a few institutional investors knocking at the door right now asking OHRP when they can put in for their allocation of shares.
The best thing in the world would be if they waited until interim results to issue shelf shares, that would be a ballsy move. R&D spend was up significantly this qtr due to more patients in trials and R&D spend is not going to come down that I can see. The cash might 'theoretically' get them to 1Q15, but at current $2M/qtr burn rate, it will be gone in the third qtr. OHRP needs working capital to pay the bills.
Prudent CEO/CFO won't wait until the bank account is empty to raise cash, especially with stock price acting well as OHRP is. Anecdotally, things are looking great for the interim readout, but who knows what might skew it badly. Why take the risk and potentially have to issue shares with your back against the wall? They don't have to do the whole $15MM, but if I were CFO/CEO, I'd be looking to put a few bucks in the bank. Remember this is a tiny offering in the grand scheme of things.
Yesterday, somebody got a sweet deal for 100 contracts of the July $12.50 Call option at $5.00. Awesome upside/downside risk/reward. I tried to get some myself when I saw that options were trading, but no luck. And I'm NOT gonna pay $6.80 for them.
Still expecting the shelf offering shares to get issued in the next couple of weeks.
Maybe I'll get a shot of some of those $5.00 July $12.50 calls then.
Where the shelf prices is going to tell us a lot about what smart money is thinking about OHRP
OT: sold the rest of my EBIO this afternoon just above $14.50. 40% in two weeks in a low downside risk trade, sometimes they just work out.
EBIO is trading really thin. Big spreads at times.
Thanks again Stuart. I'll buy you a beer if you go the the OHR shareholder meeting.
I like the way they framed it. Just the facts. Not making outrageous claims. You are allowed to draw your own conclusions.
Not sure how the stock will react with all the anticipation, but adds another brick in the wall supporting squalamine drop potential.
I emailed OHR's investor relations firm, LifeSci Advisors early last week regarding if & how Dr. Elman data would be communicated. I got a quick email reply stating that he had put in a call to OHR and would let me know when he had a response from the company.
I heard nothing back by Monday so emailed him again. Still nothing.
Usually one or both of the IR reps will respond promptly. Not this time.
Fear of Reg-FD violation? Overwhelmed with inquiries? I can't think of any other reason to not respond.
A lot of expectation built into OHRP right now. A lot of hot money. Doc Elman is going to need to come through with something good to keep it going. I guess we're going to see whether longs or shorts have more conviction.
For what it's worth I dumped my Valentines gift trading shares way early (sub $14), I only took $2 per share on them. Still holding long term shares and will continue to barring any disappointment in what we hear about tonight's presentation.
Personally, I expect OHRP to issue shares under the shelf offering in the near term with data from Dr. Elman's presentation as the catalyst to support the price. As Livermore has suggested, I think OHRP wants cash to accelerate the beginning of the PhIII trial, to get to market ASAP. Essentially start PhIII before PhII is complete, it's not unprecedented. Or they'll use the cash to do a bunch of up front work so once they do get cleared for it they'll hit the ground running.
Lets see what happens in a couple hours.
Did I tell you, did I tell you, or did I tell you????
While others are out acquiring information about their investment in OHRP, after doing his hit job today, Mr. Feuerstein tweets a picture of the craft beer he is drinking tonight.
What's he drinking you ask??? Maine Beer Company Weez Ale.
The irony of it all..... on the bottom of the beer bottle label are the words... 'Do what's right'
Oh, the irony.
Irsmith4, I got an HTML file of the 'patient Bob' testimonial page.
Are you willing to swap me for a copy of your Dr. K page screen shot?
- Previously, Bob’s newly diagnosed condition required one injection a month of Lucentis.... Currently, over his five months of check-ups, Bob did not require a single Lucentis injection. “The drops are really doing what they are supposed to, and I know Dr. Katz is as pleased as I am by the results.”-
While Feuerstein is tweeting a picture of the craft beer he is sipping at the local pub, L10 is out GETTING relevent information.
Here is a Sun Tzu quote for L10.... If you know the enemy and know yourself you need not fear the results of a hundred battles.
And yes I just added another 1/3 position in the $11.90 range. These are trading shares, expecting short sellers to cover Tuesday and expecting good data from Dr. Elman Wed.
No increase. Dr. H owns stock through AIGH Investments, 1.989,540 shares with sole dispositive power on the 13G matches up to what shows up on page 43 of last years 10K.
GCK INvestments and Charles Alperts (Cam Co) filed 13G's yesterday, again no change in qty owned.
I wish I new all SEC regulations, but these appear to be just formalities. Probably required now that they have uplisted from the Bulletin Board.
Based on the 10K ownership stats we should be seeing a few more 13G#$%$ Edgar.
Normally if the qty owned changes it's a 13Ga or 13Da (amended)
Maybe somebody else knows specifics of why they had to file.